The therapeutic potential for phospholipase A2 inhibitors

Bibliography

• GORDON BR: Asthma: an important disease to otolaryngologists - part III: anti-inflammatory therapy. Ear Nose Throat J. (1996) 75:216–224.
   PubMedGoogle Scholar
• BRENNAN FM, FELDMANN M: Cytokines in autoimmunity. Curr. Opin Immunol. (1996) 8:872–877.
   PubMed Web of Science ®Google Scholar
• CUMMINGS DM, AMADIO P: A review of selected newer non-steroidal anti-inflammatory drugs. Am. Fam. Phys. (1994) 49:1197–1202.
   PubMed Web of Science ®Google Scholar
• FELDMAN M, BRENNAN FM, MAINI RN: Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. (1996) 14:397–440.
   PubMed Web of Science ®Google Scholar
• MAINI RN, ELLIOTT MJ, BRENNAN FM, et al.: Monoclonal anti-TNF antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol. Rev (1995) 144:195–223.
   PubMed Web of Science ®Google Scholar
• MAYER RJ, MARSHALL LA: New insights on mammalian phospholipase A2(s); comparison of arachidonoyl-selective and -non-selective enzymes. FASEB J. (1993) 7:339–347.
   PubMed Web of Science ®Google Scholar
• DENNIS EA: Diversity of group types, regulation, and function of phospholipase A2. J. Biol. Chem. (1994) 269:13057–13060.
   PubMed Web of Science ®Google Scholar
• DENNIS EA: The growing phospholipase A2 superfamily of signal transduction enzymes. Trends Biochem. Sci. (1996) 22:1–2.
   Web of Science ®Google Scholar
• PRASHKER MJ, MEENAN RF: The total costs of drug therapy for rheumatoid arthritis. Arthritis Rheum. (1995) 38:318–325.
   PubMed Web of Science ®Google Scholar
• Primer on the Rheumatic Diseases. Schumacher RH (Ed.), The Arthritis Foundation, Atlanta, GA (1993) 301–306.
   Google Scholar
• LANES SF, LANZA LL, RADENSKY PW, et al.: Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. Arthr. Rheum. (1997) 40:1475–1481.
   PubMed Web of Science ®Google Scholar
• PINCUS T: The underestimated long term medical and economic consequences of rheumatoid arthritis. Drugs (1995) 50\(Suppl. 1):1–14.
   PubMed Web of Science ®Google Scholar
• ANDERSON KM, ROSHAK A, WINKLER JD, MCCORD ME, MARSHALL LA: Cytosolic 85 kDa phospholipase A2-mediated release of arachidonic acid is critical for proliferation of vascular smooth muscle cells. J. Biol. Chem. (1997) 272:30504–30511.
   PubMed Web of Science ®Google Scholar
• MARSHALL LA, BOLOGNESE B, WINKLER JD, ROSHAK A: Depletion of human monocyte 85 kDa PLA2 does not alter leukotriene formation. J. Biol. Chem. (1997) 272:759–765.
   PubMed Web of Science ®Google Scholar
• MURAKAMI M, KUWATA H, AMAKASU Y, et al.: Prostaglandin E2 amplifies cytosolic phospholipase A2- and cyclo-oxygenase-2-dependent delayed prostaglandin E2 generation in mouse osteoblastic cells. Enhancement by secretory phospholipase A2. J. Biol. Chem. (1997) 272:19891–19817.
   PubMed Web of Science ®Google Scholar
• MURAKAMI M, KUDO I, UNEDA M, et al.: Detection of three distinct phospholipases A2 in cultured mast cells. J. Biochem. (Tokyo) (1992) 111:175–181.
   PubMed Web of Science ®Google Scholar
• KRAMER RM, HESSION C, JOHANSEN B, et al.: Structure and properties of a human non-pancreatic phospholipase A2. J. Biol. Chem. (1989) 264:5768–5775.
   PubMed Web of Science ®Google Scholar
• SEILHAMER JJ, PRUZANSKI W, VADAS P, et al.: Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. J. Biol. Chem. (1989) 264:5335–5338.
   PubMed Web of Science ®Google Scholar
• CHEN J, ENGLE SJ, SEILHAMER JJ, TISCHFIELD JA: Cloning and characterization of novel rat and mouse low molecular weight Ca2+-dependent phospholipase A2s containing 16 cysteines. J. Biol. Chem. (1994) 269:23018–23024.
   PubMed Web of Science ®Google Scholar
• TISCHFIELD JA: A reassessment of the low molecular weight phospholipase A2 gene family in mammals. J. Biol. Chem. (1997) 272:17247–17250.
   PubMed Web of Science ®Google Scholar
• CLARK JD, SCHIEVELLA AR, NALEFSKI EA, LIN LL: Cytosolic phospholipase A2. J. Lipid Media. Cell Signal. (1995) 12:83–117.
   PubMedGoogle Scholar
• DIEZ E, CHILTON FH, STROUP G, et al.: Fatty acid and phospholipid selectivity of different phospholipase A2 enzymes studied by using a mammalian membrane as substrate. Biochem. J. (1994) 301:721–726.
   PubMed Web of Science ®Google Scholar
• SCHIEVELLA AR, REGIER MK, SMITH WL, LIN LL: Calcium-mediated translocation of cytosolic phospholipase A2 to the nuclear envelope and endoplasmic reticulum. J. Biol. Chem. (1995) 270:30749–30754.
   PubMed Web of Science ®Google Scholar
• STREET IP, LIN HK, LALIBERTE F, et al.: Slow- and tight-binding inhibitors of the 85-kD human phospholipase A2. Biochemistry (1993) 32:5935–5940.
   PubMed Web of Science ®Google Scholar
• KRAMER RM, ROBERTS EF, MANETTA JV, HYSLOP PA, JAKUBOWSKI JA: Thrombin-induced phosphorylation and activation of Ca2+-sensitive cytosolic phospholipase A2 in human platelets. J. Biol. Chem. (1993) 268:26796–26804.
   PubMed Web of Science ®Google Scholar
• BORSCH-HAUBOLD AG, KRAMER RM, WATSON SP: Phosphorylation and activation of cytosolic phospholipase A2 by 38 kDa mitogen-activated kinase in collagen stimulated human platelets. Eur. J. Biochem. (1997) 245:751–759.
   PubMedGoogle Scholar
• MARSHALL LA, HALL RH, WINKLER JD, et al.: SB 203347, an inhibitor of 14 kDa phospholipase A2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine endotoxin shock. J. Pharmacol. Exp. Ther. (1995) 274:1254–1262.
   PubMed Web of Science ®Google Scholar
• TRAMPOSCH KM, CHILTON FH, STANLEY PL, et al.: Inhibitor of phospholipase A2 blocks eicosanoid and platelet activating factor biosynthesis and has topical anti-inflammatory activity. J. Pharmacol. Exp. Ther. (1994) 271:852–859.
   PubMed Web of Science ®Google Scholar
• SCHEVITZ RW, BACH NJ, CARLSON DG, et al.: Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. Nature Struct. Biol. (1995) 2:458–465.
   PubMedGoogle Scholar
• GLASER KB, SUNG ML, LOCK YW, et al.: WAY-125984, a novel and selective inhibitor of phospholipase A2. Inflammation Research Association (1994) W36. Abstract.
   Google Scholar
• LEMAHIEU RA, CARSON M, HAN RJ: N-(Carboxymethyl)-N- [3,5-bis(decyloxy)-phenyl]glycine (Ro 23-9358): a potent inhibitor of secretory phospholipases A2 with anti-inflammatory activity. J. Med. Chem. (1993) 36:3029–3031.
   PubMed Web of Science ®Google Scholar
• MIYAKE A, YAMAMOTO H, TAKEBAYASHI Y, IMAI H, HONDA K: The novel natural product YM-26567-1 ((+)-trans-4-(3-dodecanoy1-2,4,6-trihydroxyphenyl) -7-hydroxy-2-(4-hydroxyphenyl) chroman]: a competitive inhibitor of group II phospholipase A2. J. Pharmacol. Exp. Ther. (1992) 263:1302–1307.
   PubMed Web of Science ®Google Scholar
• MARSHALL LA, WINKLER JD, GRISWOLD DE, et al.: Effects of scalaradial, a Type II phospholipase A2 inhibitor, on human neutrophil arachidonic acid mobilization and lipid mediator formation. J. Pharmacol. Exp. Ther. (1994) 268:1–9.
   PubMed Web of Science ®Google Scholar
• MAYER RJ, MARSHALL LA: Therapeutic regulation of 14 kDa phospholipase A2(s). Exp. Opin. Invest. Drugs (1996) 5:535–553.
   Google Scholar
• JACKSON JR, BOLOGNESE B, MANAGER CA, et al.: The products of 14 kDa phospholipase A2 action, particularly platelet activating factor, contribute to inflammatory angiogenesis. Biochim. Biophys. Acta. (In press).
   Google Scholar
• SCHALKWIJK C, DE VET E, PFEILSCHIFTER J, VAN DEN BOSCH H: Interleukin-10 and transforming growth factor-f32 enhance cytosolic high-molecular-mass phospholipase A2 activity and induce prostaglandin E2 formation in rat mesangial cells. Eur. J. Biochem. (1992) 210:169–176.
   PubMedGoogle Scholar
• BAUDRY SA, WOOTEN RE, BASS DA: Activation of cytosolic phospholipase A2 in permeabilized human neutrophils. Biochim. Biophys. Acta (1996) 1299:223–234.
   PubMed Web of Science ®Google Scholar
• BARTOLI F, LIN H-K, GHOMASHCHI F, et al.: Tight binding inhibitors of 85-kDa phospholipase A2 but not 14-kDa phospholipase A2 inhibit release of free arachidonate in thrombin-stimulated human platelets. J. Biol. Chem. (1994) 269:15625–15630.
   PubMed Web of Science ®Google Scholar
• RIENDEAU D, GUAY J, WEECH PK, et al.: Arachidonyl trifluoromethyl ketone, a potent inhibitor of 85-kDa phospholipase A2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. J. Biol. Chem. (1994) 269:15619–15624.
   PubMed Web of Science ®Google Scholar
• AMANDI-BURGERMEISTER E, TIBES U, KAISER BM, FRIEBE WG, SCHEUER WV: Suppression of cytokine synthesis, integrin expression and chronic inflammation by inhibitors of cytosolic phospholipase A2. Eur. J. Pharmacol. (1997) 326:237–250.
   PubMed Web of Science ®Google Scholar
• BALSINDE J, DENNIS EA: Function and inhibition of intracellular calcium-independent phospholipase A2. J. Biol. Chem. (1997) 272:16069–16072.
   PubMed Web of Science ®Google Scholar
• HAZEN SL, ZUPAN LA, WEISS RH, GETMAN DP, GROSS RW: Suicide inhibition of canine myocardial cytosolic calcium independent phospholipase A2. J. Biol. Chem. (1991) 266:7227–7232.
   PubMed Web of Science ®Google Scholar
• Glaser K, Band, Vadas P (Eds.), CRC Press, Boca Raton, FL (1995):127–147.
   Google Scholar
• GRASS DS, FELKNER RH, CHIANG M-Y, BENNETT CF, SWANSON ME: Human extracellular (type II) phospholipase A2 (PLA2) transgenic mice provide a mouse model for evaluation of PLA2 inhibitors. Arthr. Rheum. (1993) 36:S293.
   Google Scholar
• CHAPDELAINE JM, CIOFALO VB, GRASS DS, et al.: Human extracellular (type II) phospholipase A2 (PLA2) transgenic mice provide a tool to determine the role of PLA2 in inflammatory conditions. Arthr. Rheum. (1995) 38:S293.
   Web of Science ®Google Scholar
• WISSING D, MOURTITZEN H, EGEBLAD M, POIRIER GG, JAATTELA M: Involvement of caspase-dependent activation of cytosolic phospholipase A2 in tumor necrosis factor-induced apoptosis. Proc. Natl. Acad. Sci. USA (1997) 94:5073–5077.
   PubMed Web of Science ®Google Scholar
• LEHR M: Synthesis, biological evaluation and structure-activity relationships of 3-acylindole-2-carbocylic acids as inhibitors of cytosolic phospholipase A2. J. Med. Chem. (1997) 40:2694–2705.
   PubMed Web of Science ®Google Scholar